Comparative Pharmacology
Head-to-head clinical analysis: PEDIATRIC LTA KIT versus XYLOCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEDIATRIC LTA KIT versus XYLOCAINE.
PEDIATRIC LTA KIT vs XYLOCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PEDIATRIC LTA KIT contains lidocaine, tetracaine, and epinephrine. Lidocaine and tetracaine are amide and ester local anesthetics, respectively, that block voltage-gated sodium channels, preventing nerve impulse propagation. Epinephrine is a sympathomimetic that causes vasoconstriction, prolonging local anesthetic effect and reducing systemic absorption.
Lidocaine binds to and inhibits voltage-gated sodium channels in the neuronal membrane, stabilizing the membrane and preventing the initiation and conduction of nerve impulses, thereby producing local anesthesia.
Not applicable. Pediatric LTA Kit is a topical lidocaine/tetracaine patch for dermal anesthesia. Adult dose: apply one patch to intact skin for 20-30 minutes prior to procedure; remove prior to procedure. Maximum 3 patches per session. Not for systemic use.
1-5 mg/kg (max 300 mg) local infiltration; epidural: 1-2% solution, 5-20 mL.
None Documented
None Documented
2-3 hours (terminal) in children with normal renal function; prolonged in renal impairment
Terminal elimination half-life is approximately 1.5 to 2 hours in adults, prolonged to 2-3 hours in patients with hepatic impairment, and may exceed 5 hours in neonates or patients with heart failure.
Renal (95% as unchanged drug), fecal (5%)
Hepatic metabolism (primarily by CYP1A2 and CYP3A4) to metabolites, mainly monoethylglycinexylidide (MEGX) and glycinexylidide (GX); less than 10% excreted unchanged in urine. Renal excretion of metabolites: MEGX (70-80%) and GX (10-20%). Biliary/fecal elimination is minimal.
Category C
Category C
Local Anesthetic
Local Anesthetic